# B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome

> **NCT01156909** · PHASE2 · COMPLETED · sponsor: **Haukeland University Hospital** · enrollment: 29 (actual)

## Conditions studied

- Chronic Fatigue Syndrome
- Myalgic Encephalomyelitis

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01156909
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156909, "B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01156909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*